Eli Lilly says it has “no affiliation” with Hims & Hers after market confusion
said in a statement Tuesday evening that it has “no affiliation” with Hims & Hers after the market appeared to briefly misinterpret a statement from the telehealth platform as some sort of partnership...
Hims & Hers to sell Eli Lilly’s Zepbound on its platform
shares rose Tuesday afternoon after the telehealth company said it would offer blockbuster weight-loss drug Zepbound on its platform. The move gives Hims & Hers a way to offer its users the cutting e...
Moderna stock drops after FDA vaccine chief resigns
Moderna shares fell 10% in premarket trading Monday morning after reports that the Food and Drug Administration’s vaccine chief, Peter Marks, resigned from the agency on Friday. In his resignation let...
Eli Lilly’s Alzheimer’s drug gets thumbs down from EU regulator
blockbuster Alzheimer’s disease medication, Kisunla, was not approved for use by the European Union’s drug regulator, who said its benefits don’t outweigh the risks of swelling and bleeding in the bra...
Is Ozempic old news?
Ozempic, a drug developed by Novo Nordisk to treat type 2 diabetes, entered the market in December 2017. Then people without diabetes learned it’s really good at making people lose weight. Next came t...
CVS Health is the best performing stock in the S&P 500 this year
This year's top performing stock is none other than , which is leading healthcare stocks' healthy comeback in the . The massive drugstore franchise has returned 46% to date this year, thanks to its fo...
Novo Nordisk dips after latest trial on its new weight-loss drug disappoints
Novo Nordisk shares fell after the results for the latest trial of its next-generation weight-loss shot, CagriSema, disappointed investors as the race for the next miracle weight-loss drug heats up. C...
Hims & Hers falls after a court ruling on a drug it never sold
Hims & Hers shares fell Thursday after more news poured in continuing to drive the point home that the tele-pharmacy likely can’t count on selling a significant amount of copycat Ozempic and Wegovy. A...
German court rules Pfizer violated Moderna Covid vaccine patent, sending Moderna even higher
Moderna shares are rising after a German court handed the vaccine maker a win in a patent lawsuit against Pfizer. The court ruled that Pfizer and BioNTech violated a COVID-19 vaccine patent held by , ...
Hims & Hers falls after Novo Nordisk launches discounted Wegovy for uninsured
Hims & Hers shares fell and Novo Nordisk shares rose after the drugmaker announced Wednesday morning that it launched a telehealth platform, NovoCare, designed to give uninsured patients access to Weg...
Moderna rises after $6 million in insider purchases revealed
Moderna’s share price is spiking after the company disclosed early Wednesday that CEO Stephane Bancel and Board Director Paul Sagan have purchased $6 million worth of the company’s stock. According t...
Here’s how Hims & Hers will pivot now that it can’t mass produce copies of Wegovy and Ozempic
Hims & Hers has skidded 40% since the Food and Drug Administration declared that semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — is no longer in a shortage, complicating the...
Hims & Hers investors run for the hills despite earnings beat and cheery outlook
Hims & Hers Health, the tele-pharmacy known for selling copycat versions of popular weight-loss drugs, tanked in aftermarket trading despite largely meeting Wall Street expectations and giving upbeat ...
Hims & Hers falls, Novo Nordisk rises after FDA says Ozempic shortage is over
The popular weight-loss drugs Ozempic and Wegovy are no longer in a shortage, the Food and Drug Administration said Friday , making it more difficult for telepharmacies to sell copycat versions. Share...
Hims & Hers to provide at-home blood testing with new acquisition
Hims & Hers’ share price shot up more than 15% after the company announced it had acquired at-home lab testing facility Trybe Labs. , an online pharmacy best known for selling knock-off versions of we...
Moderna misses in Q4, stock does what it’s done for nearly 8 months straight: goes down
Moderna shares slipped in early trading after the vaccine maker missed Wall Street estimates. reported a $2.91 loss per share, compared to the $2.68 loss per share analysts polled by FactSet were expe...
Hims & Hers jumps after RFK Jr. confirmation
Hims & Hers rose more than 27% on Thursday after Robert F. Kennedy Jr. was confirmed to lead the Department of Health and Human Services. Kennedy, a vaccine skeptic hostile to Big Pharma, was one of t...
Eli Lilly, Novo Nordisk sold more than $40 billion in GLP-1 drugs in 2024
For Eli Lilly and Novo Nordisk, the present and future are about weight-loss drugs. The two companies dominate the market for GLP-1 drugs, which are prescribed for diabetes and obesity. Mounjaro and ...
Novo Nordisk gains because of its weight-loss drugs
Novo Nordisk rose in early trading after it reported better-than-expected earnings propped up by even more growth in its weight-loss drugs. The company reported $3.9 billion in net income in the last ...
Merck getting merc’d after cutting Gardasil sales to China
Merck & Co. shares are down more than 10% on Tuesday after the drugmaker gave a gloomy guidance for 2025, in part because it will pause shipments of its HPV vaccine to China until at least midyear. Th...